Three Human Trials, Three Unrelated Diseases, One Surprising Conclusion About Aging
Three recent human trials on mTOR inhibitors in hypertrophic cardiomyopathy, chronic fatigue syndrome, and ovarian aging look unrelated on the surface. The cellular data suggests they might be pointing at the same upstream problem, though it is worth being careful about how far to push that interpretation. In each disease state, growth programs appear to stay chronically active past their developmental purpose while maintenance systems like autophagy and protein recycling fall progressively behind.
Whether that is a unified mechanism or a convenient narrative imposed on three separate datasets is a fair question. None of the trials were designed to measure longevity directly. The jump from short-term functional improvements to conclusions about aging biology seems to be a long one.
I think the framing around chronic mTOR overactivation as a conserved feature of age-related pathology across human tissue is compelling. Worth reading if you want to see the mechanistic thread being drawn across the three trials and form your own view on how far it holds up.